RxGen Revenue and Competitors

RxGen, Inc. is a privately held biotechnology company that leverages highly predictive pre-clinical models of human disease to accelerate the drug development process. Using primate models of central nervous system (CNS) disorders, metabolism (obesity & diabetes), ophthalmic diseases, and other disease states, new therapeutics can be rapidly evaluated for efficacy. Our advanced capabilities in phenotypic analysis including neurobehavioral testing, physiology, biochemistry, SPECT imaging, functional genomics and bioinformatics provide an unparalleled opportunity to evaluate drug delivery and efficacy. Our proprietary PrimaTox™ toxicogenomics program, available through our subsidiary RxGen PrimaTox, allows direct in vivo assessment of drug toxicity using traditional methodologies and advanced genomic approaches to facilitate predictive toxicology in a human-relevant model